Pearce IP BioBlast: w/e 01 January 2021
Significant biosimilar activities this week include:
27 Dec 20, CN: Innovent announced China's NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional indication of adult recurrent glioblastoma.
30 Dec 20: Alvotech announced it has broken ground on the extension to its high-tech centre in Reykjavik. The extension will house biosimilar development, drug refills, offices and warehouses, and is expected to be completed by the end of 2022.